What actually helps while psilocybin is unavailable
If you read this site and came away with nowhere to go
That is the accurate conclusion, and it is not a satisfying one. Psilocybin has no prescription route in the United States, two jurisdictions offer supervised access at a price most people cannot pay, and of 133 open trials only 8 are at the stage that could support an approval. A publication that reports that honestly owes its readers the things that are available.
A psilocybin trial does not test a drug
It tests a package. Every trial wraps the dose in preparation, monitoring by two trained people throughout, and integration afterward. That structure is part of the intervention being tested rather than packaging around it — and no adequately designed study has separated how much of the benefit belongs to the compound and how much to the many hours of skilled human attention around it.
Available today
Preparation
Sessions before the dose, setting expectations and building trust.
Out of reach
The compound
Schedule I. No prescription route. Two states, in person, out of pocket.
Available today
Monitoring
Two trained people present for the whole session.
Available today
Integration
Structured sessions afterward, making sense of what happened.
The missing-ingredient problem is the most-cited weakness in this evidence base, and we say so on our safety and limitations page. It cuts the other way too, and that half is rarely said out loud: if the therapeutic structure is doing a meaningful share of the work, three of those four parts are available to you now, without a Schedule I substance and without waiting for the FDA.
What carries more evidence than psilocybin does
None of this is exciting. All of it is better established than anything on this site’s evidence pages.
For depression
- Cognitive behavioral therapyLargest and most replicated evidence base in psychiatry
- Behavioral activationComparable footing, and simpler to deliver
- Interpersonal therapyWell supported
Orders of magnitude more participants than the entire psilocybin literature.
For PTSD
- Prolonged exposureVA/DoD Clinical Practice Guideline
- Cognitive processing therapyVA/DoD Clinical Practice Guideline
- EMDRVA/DoD Clinical Practice Guideline
Neither psilocybin nor MDMA appears in that guideline, and both are marketed heavily to veterans.
Telehealth, and where the line is
Psilocybin by mail or video
Illegal
Schedule I, no prescription route, and Oregon and Colorado both require administration in person at a licensed location. Any service offering it this way is operating illegally, however it describes itself.
Talk therapy by telehealth
Good evidence
Remotely delivered CBT performs comparably to in-person delivery across a substantial literature. For most people reading this page, this is the most accessible evidence-supported step available today.
At-home ketamine by telehealth
Contested
Legal in a repeatedly extended regulatory space. The clinical objection is separate from the legal one: dosing without monitoring removes the supervision every clinic and trial protocol treats as necessary.
What we are not going to do
We refer nobody anywhere, take no commission from any provider, and will not publish a list of therapists we have not assessed. Finding a clinician is genuinely hard, and a directory we have not built would not solve it. What we can say: the search terms that work are the modality names above, and asking a prospective therapist which of them they are trained in is a reasonable and normal question.
Questions people ask
- Can I get psilocybin therapy through telehealth?
- No. Psilocybin is a Schedule I substance with no federal prescription route, so no telehealth provider can lawfully prescribe or supply it. Oregon and Colorado's supervised programs require in-person administration at a licensed location. Any service offering psilocybin by mail or by video consultation is operating illegally, whatever the framing.
- Is ketamine therapy available by telehealth?
- At-home ketamine by telehealth exists and operates in a genuinely contested regulatory space. Ketamine is Schedule III, so it can be prescribed remotely under the flexibilities that followed the COVID-19 public health emergency, and those flexibilities have been extended repeatedly rather than made permanent. The clinical concern is separate from the legal one: unsupervised dosing at home removes the monitoring that clinic and trial protocols treat as essential.
- What talk therapy has the strongest evidence for depression?
- Cognitive behavioral therapy and behavioral activation have the largest and most replicated evidence bases for depression, and interpersonal therapy is well supported. For PTSD specifically, the VA/DoD Clinical Practice Guideline recommends trauma-focused psychotherapies — prolonged exposure, cognitive processing therapy and EMDR — and it is worth noting that neither psilocybin nor MDMA appears in that guideline.
- Is the therapy or the drug doing the work in psychedelic trials?
- Nobody knows, and that is one of the field's central unresolved problems rather than a rhetorical point. Every psilocybin trial delivers the dose inside a structure of preparation, in-session monitoring and integration sessions with trained people. No adequately designed study has separated the contribution of the drug from the contribution of that structure. It is a real weakness in the evidence — and it is also a reason to take the therapeutic component seriously on its own terms.